Full Press Release Details
dupixent dupilumab sbla accepted for fda priority review for treatment of copd with type 2 inflammation.
REGN
dupixent dupilumab sbla accepted for fda priority review for treatment of copd with type 2 inflammation
Key Takeaway: dupixent dupilumab sbla accepted for fda priority review for treatment of copd with type 2 inflammation